CPT® Code 0708T

Intradermal cancer immunotherapy represents a significant advancement in cancer treatment, focusing on harnessing the body's immune system to combat cancerous cells. Unlike traditional chemotherapy, which directly targets and kills cancer cells, immunotherapy aims to stimulate and enhance the immune response, enabling the body to identify and destroy cancer cells more effectively. This approach is particularly beneficial as it can lead to more targeted treatment strategies, reducing the collateral damage often associated with systemic therapies. The administration of immunotherapy can, however, lead to serious side effects in some patients, including cytokine release syndrome, vascular leak syndrome, and autoimmune reactions, which can be severe or even fatal. The method of delivery for immunotherapy is crucial; intradermal injections are preferred over subcutaneous injections due to the higher concentration of dendritic cells in the dermis. These cells play a vital role in capturing antigens and migrating to the lymph nodes, where they stimulate T-cells, thereby amplifying the immune response against tumors. The CPT® Code 0708T is specifically designated for the preparation and initial injection of this innovative immunotherapy treatment, while subsequent injections are reported using CPT® Code 0709T.